Impact of CXCR4 inhibition on FLT3-ITD-positive human AML blasts

Experimental Hematology

Volumn 38, Issue 3, 2010, Pages 180-190

  Jacobi, Angela ^a   Thieme, Sebastian ^a,b   Lehmann, Romy ^a   Ugarte, Fernando ^a   Malech, Harry L ^c   Koch, Sina ^a   Thiede, Christian ^a,b   Müller, Katrin ^a   Bornhäuser, Martin ^a,b   Ryser, Martin ^a   Brenner, Sebastian ^a,b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; CD34 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; PLERIXAFOR; RETROVIRUS VECTOR; STROMAL CELL DERIVED FACTOR 1;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLAST CELL; CELL HOMING; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; GENE OVEREXPRESSION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MIGRATION INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; TRANSGENE; WILD TYPE;

ACUTE DISEASE; ANIMALS; BONE MARROW CELLS; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; FLOW CYTOMETRY; FMS-LIKE TYROSINE KINASE 3; HEMATOPOIETIC STEM CELLS; HETEROCYCLIC COMPOUNDS; HUMANS; LEUKEMIA, EXPERIMENTAL; LEUKEMIA, MYELOID; MICE; MICE, INBRED NOD; MICE, SCID; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUTATION; PHOSPHORYLATION; RECEPTORS, CXCR4; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STAT3 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR; TRANSPLANTATION, HETEROLOGOUS; TUMOR SUPPRESSOR PROTEINS;

MUS;

EID: 76749151991     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2009.12.003     Document Type: Article

References (28)

1. Gilliland D.G. FLT3-activating mutations in acute promyelocytic leukaemia: A rationale for risk-adapted therapy with FLT3 inhibitors. Best Pract Res Clin Haematol 16 (2003) 409-417
2. Lee B.H., Tothova Z., Levine R.L., et al. FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia. Cancer Cell 12 (2007) 367-380
3. Mizuki M., Fenski R., Halfter H., et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 96 (2000) 3907-3914
4. Kiyoi H., Naoe T., Nakano Y., et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 93 (1999) 3074-3080
5. Thiede C., Steudel C., Mohr B., et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99 (2002) 4326-4335
6. Matsunaga T., Takemoto N., Sato T., et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 9 (2003) 1158-1165
7. Tavor S., Petit I., Porozov S., et al. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res 64 (2004) 2817-2824
8. Jin L., Hope K.J., Zhai Q., Smadja-Joffe F., and Dick J.E. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 12 (2006) 1167-1174
9. Broxmeyer H.E., Kohli L., Kim C.H., et al. Stromal cell-derived factor-1/CXCL12 directly enhances survival/antiapoptosis of myeloid progenitor cells through CXCR4 and G[alpha]i proteins and enhances engraftment of competitive, repopulating stem cells. J Leukoc Biol 73 (2003) 630-638
10. Zeng Z., Shi Y.X., Samudio I.J., et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 113 (2009) 6215-6224
11. Liesveld J.L., Bechelli J., Rosell K., et al. Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells. Leuk Res 31 (2007) 1553-1563
12. Juarez J., Dela P.A., Baraz R., et al. CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment. Leukemia 21 (2007) 1249-1257
13. Nervi B., Ramirez P., Rettig M.P., et al. Chemosensitization of acute myeloid leukemia [AML] following mobilization by the CXCR4 antagonist AMD3100. Blood 113 (2009) 6206-6214
14. Rombouts E.J., Pavic B., Lowenberg B., and Ploemacher R.E. Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood 104 (2004) 550-557
15. Fukuda S., Broxmeyer H.E., and Pelus L.M. Flt3 ligand and the Flt3 receptor regulate hematopoietic cell migration by modulating the SDF-1alpha[CXCL12]/CXCR4 axis. Blood 105 (2005) 3117-3126
16. Koch S., Jacobi A., Ryser M., Ehninger G., and Thiede C. Abnormal localization and accumulation of FLT3-ITD, a mutant receptor tyrosine kinase involved in leukemogenesis. Cells Tissues Organs 188 (2008) 225-235
17. Brenner S., Whiting-Theobald N.L., Linton G.F., et al. Concentrated RD114-pseudotyped MFGS-gp91phox vector achieves high levels of functional correction of the chronic granulomatous disease oxidase defect in NOD/SCID/beta- microglobulin-/- repopulating mobilized human peripheral blood CD34+ cells. Blood 102 (2003) 2789-2797
18. Brenner S., Ryser M.F., Whiting-Theobald N.L., Gentsch M., Linton G.F., and Malech H.L. The late dividing population of gamma-retroviral vector transduced human mobilized peripheral blood progenitor cells contributes most to gene-marked cell engraftment in nonobese diabetic/severe combined immunodeficient mice. Stem Cells 25 (2007) 1807-1813
19. Jo D.Y., Rafii S., Hamada T., and Moore M.A. Chemotaxis of primitive hematopoietic cells in response to stromal cell-derived factor-1. J Clin Invest 105 (2000) 101-111
20. Soriano S.F., Hernanz-Falcon P., Rodriguez-Frade J.M., et al. Functional inactivation of CXC chemokine receptor 4-mediated responses through SOCS3 up-regulation. J Exp Med 196 (2002) 311-321
21. Fukuda S., and Pelus L.M. Internal tandem duplication of Flt3 modulates chemotaxis and survival of hematopoietic cells by SDF1alpha but negatively regulates marrow homing in vivo. Exp Hematol 34 (2006) 1041-1051
22. Pello O.M., Moreno-Ortiz M.C., Rodríguez-Frade J.M., et al. SOCS up-regulation mobilizes autologous stem cells through CXCR4 blockade. Blood 108 (2006) 3928-3937
23. Choudhary C., Brandts C., Schwable J., et al. Activation mechanisms of STAT5 by oncogenic Flt3-ITD. Blood 110 (2007) 370-374
24. Schuringa J.J., Wierenga A.T., Kruijer W., et al. Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. Blood 95 (2000) 3765-3770
25. Mizuki M., Fenski R., Halfter H., et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 96 (2000) 3907-3914
26. Tavor S., Eisenbach M., Jacob-Hirsch J., et al. The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation. Leukemia 22 (2008) 5151-5158
27. Fierro F.A., Brenner S., Oelschlaegel U., et al. Combining SDF-1/CXCR4 antagonism and chemotherapy in relapsed acute myeloid leukemia. Leukemia 23 (2008) 393-396
28. Hendrix C.W., Collier A.C., Lederman M.M., et al. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 37 (2004) 1253-1262